StockNews.com Initiates Coverage on ChromaDex (NASDAQ:CDXC)

Equities researchers at StockNews.com began coverage on shares of ChromaDex (NASDAQ:CDXC) in a research report issued to clients and investors on Saturday. The brokerage set a “buy” rating on the stock.

A number of other brokerages also recently weighed in on CDXC. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of ChromaDex in a research report on Monday, March 17th. LADENBURG THALM/SH SH boosted their target price on ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a research note on Wednesday, March 5th.

ChromaDex Stock Performance

ChromaDex has a 52 week low of $2.31 and a 52 week high of $9.18. The business’s 50 day moving average is $6.16 and its two-hundred day moving average is $5.44. The firm has a market capitalization of $611.50 million, a PE ratio of 787.29 and a beta of 2.21.

Institutional Investors Weigh In On ChromaDex

Several institutional investors have recently added to or reduced their stakes in CDXC. Price T Rowe Associates Inc. MD raised its stake in shares of ChromaDex by 4.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 57,304 shares of the company’s stock valued at $304,000 after purchasing an additional 2,196 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of ChromaDex by 3.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 144,621 shares of the company’s stock worth $767,000 after buying an additional 4,452 shares in the last quarter. USA Financial Formulas acquired a new stake in ChromaDex in the 4th quarter valued at approximately $25,000. BSW Wealth Partners lifted its stake in ChromaDex by 5.6% in the 4th quarter. BSW Wealth Partners now owns 93,847 shares of the company’s stock valued at $498,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Teton Advisors Inc. boosted its position in ChromaDex by 25.0% during the 4th quarter. Teton Advisors Inc. now owns 25,000 shares of the company’s stock worth $133,000 after acquiring an additional 5,000 shares during the last quarter. 15.41% of the stock is owned by institutional investors.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.